|Assessment Status||Rapid review complete|
|Indication||In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.|
|Rapid review commissioned||06/12/2018|
|Rapid review completed||16/01/2019|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that doravirine (Pifeltro®) not be considered for reimbursement at the submitted price.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.